9月23日，深圳华大基因股份有限公司公告披露，控股股东深圳华大基因科技有限公司(华大控股)及其 一致行动人汪建、深圳华大三生园科技有限公司发生权益变动。汪建现任华大基因董事长、华大控股董 事长，其通过询价转让方式出让1673.27万股股份，占公司总股本的4.00%，成交价格为44.10元/股，交 易金额约7.38亿元。事实上，这已是华大控股今年的第二次大额减持。两次合计，汪建及华大控股在 2025年已减持套现金额超过11亿元。 由于华大控股为汪建全资控制企业，这意味着，其实际套现超过7亿元。本次交易共有29家基金公司接 盘，其中包括易方达、财通、华夏、诺德、国泰等头部机构。 事实上，这已是华大控股今年的第二次大额减持。3月11日至14日，公司曾通过大宗交易累计减持 748.83万股，套现约4.2亿元。 两次合计，汪建及华大控股在2025年已减持套现金额超过11亿元。 市场普遍认为，尽管机构积极参与，但创始人及控股股东的集中减持仍释放出资金压力与战略收缩的信 号。 现状 华大基因上半年营收降近13% 华大控股今年二次大额减持 交易完成后，华大控股持股比例降至29.77%，汪建直接持股0.61%，三生园科技持股0 ...

Group 1 - The core point of the news is that Shenzhen BGI Genomics Co., Ltd. (300676.SZ) is experiencing significant shareholder equity changes and operational challenges, leading to concerns about its future prospects [2][4]. - The controlling shareholder, Shenzhen BGI Technology Co., Ltd., and its associates have reduced their stake by 4% through a share transfer, raising approximately 738 million yuan [2]. - Following this transaction, the combined shareholding of the three parties decreased from 38.17% to 31.32%, indicating a significant cash-out by the founder and controlling shareholder [2]. Group 2 - BGI Genomics reported a 12.82% year-on-year decline in revenue for the first half of 2025, totaling 1.631 billion yuan, with a net profit drop of 68.25% to 5.7782 million yuan [3]. - The company faced a net cash flow deficit of 414 million yuan, a decline of over four times compared to the previous year, indicating worsening operational cash flow [3]. - The fertility health business saw a revenue drop of 29.8%, while the tumor and chronic disease prevention business revenue fell by 27.52%, highlighting the company's reliance on external partnerships [3]. Group 3 - Another major shareholder, Shenzhen Shenghua Investment Enterprise, announced plans to reduce its stake by up to 627,480 shares within three months, further intensifying market concerns about the company's outlook [4]. - Industry experts identify three main challenges for BGI Genomics: intensified price competition in traditional businesses, high dependency on partners for new businesses, and uncertainties in overseas markets due to geopolitical factors [5]. - The company's ability to achieve breakthroughs in direct-to-consumer sales and leverage emerging markets and new technologies will be crucial for returning to a growth trajectory [5].

在全球产业链重构与科技博弈加剧的当下，"自主可控+国产替代"正演化成资本市场最清晰的价值锚点。在这轮时代大考中， 真正具备底层创新能力的科技企业正显露出穿越周期的韧性。 行业承压寻突破，结构韧性谋新篇 在行业整体承压的背景下，华大基因2024年度报告呈现出独特的结构韧性。在逆周期环境中仍勾勒出清晰的发展脉络。 在生育健康领域，尽管新生儿出生率持续走低，华大基因却凭借其在该领域的深厚积累与前瞻布局，展现出相对稳健的态 势。其中新生儿遗传病基因筛查业务营业收入同比增长约47.38%；辅助疾病临床诊断方向的遗传病基因检测系列业务营业收 入同比增长约53.13%。 公司不仅构建了覆盖婚前、孕前、孕期、新生儿及儿童全周期的出生缺陷三级防控体系，还通过精准定位民生需求，成功承 接了多地如广州、杭州等地推广孕妇外周血胎儿游离DNA产前筛查及出生缺陷检测服务项目，有效促进了出生缺陷的预防与 减少，也进一步提升了其业务渗透率。 市场前景上来看，公司积极持续拓展产品布局，优化成本以及国产率，将基因检测从二级预防向一级以及三级预防业务不断 延伸，向外扩展业务边际，在提高市场渗透率的同时向上打开市场空间。 同时，华大基因在肿瘤与慢病 ...